Autolus Therapeutics (AUTL) Competitors $2.49 -0.09 (-3.49%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends AUTL vs. BHC, ARWR, DYN, CPRX, HCM, AGIO, PTGX, IOVA, AMRX, and LBPHShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Dyne Therapeutics (DYN), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Iovance Biotherapeutics (IOVA), Amneal Pharmaceuticals (AMRX), and Longboard Pharmaceuticals (LBPH). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Bausch Health Companies Arrowhead Pharmaceuticals Dyne Therapeutics Catalyst Pharmaceuticals HUTCHMED Agios Pharmaceuticals Protagonist Therapeutics Iovance Biotherapeutics Amneal Pharmaceuticals Longboard Pharmaceuticals Bausch Health Companies (NYSE:BHC) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking. Does the MarketBeat Community favor BHC or AUTL? Bausch Health Companies received 133 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 67.87% of users gave Autolus Therapeutics an outperform vote while only 61.47% of users gave Bausch Health Companies an outperform vote. CompanyUnderperformOutperformBausch Health CompaniesOutperform Votes35961.47% Underperform Votes22538.53% Autolus TherapeuticsOutperform Votes22667.87% Underperform Votes10732.13% Which has more risk & volatility, BHC or AUTL? Bausch Health Companies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Do insiders & institutionals have more ownership in BHC or AUTL? 78.7% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 8.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, BHC or AUTL? Autolus Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Companies$9.47B0.29-$592M-$0.48-16.00Autolus Therapeutics$10.09M65.66-$208.38M-$1.21-2.06 Do analysts rate BHC or AUTL? Bausch Health Companies currently has a consensus price target of $7.75, suggesting a potential upside of 0.91%. Autolus Therapeutics has a consensus price target of $10.40, suggesting a potential upside of 317.67%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Bausch Health Companies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BHC or AUTL more profitable? Autolus Therapeutics has a net margin of 0.00% compared to Bausch Health Companies' net margin of -1.88%. Autolus Therapeutics' return on equity of -63.65% beat Bausch Health Companies' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Companies-1.88% -755.86% 5.11% Autolus Therapeutics N/A -63.65%-36.54% Does the media prefer BHC or AUTL? In the previous week, Bausch Health Companies had 5 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Bausch Health Companies and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.71 beat Bausch Health Companies' score of 0.57 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Companies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAutolus Therapeutics beats Bausch Health Companies on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$662.57M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-2.0646.24135.3117.54Price / Sales65.66420.221,260.42139.42Price / CashN/A182.1340.5837.95Price / Book3.893.924.884.92Net Income-$208.38M-$42.03M$118.89M$225.78M7 Day Performance-14.14%-3.37%15.96%-1.56%1 Month Performance-16.72%7.95%15.87%6.68%1 Year Performance-51.93%21.00%34.78%22.48% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.8365 of 5 stars$2.49-3.5%$10.40+317.7%-50.3%$662.57M$10.09M-2.06330BHCBausch Health Companies2.7339 of 5 stars$7.68-1.7%$7.75+0.9%+5.5%$2.78B$8.76B-16.2720,270Short Interest ↑ARWRArrowhead Pharmaceuticals4.2954 of 5 stars$22.12+1.2%$42.70+93.0%-22.0%$2.75B$3.55M-4.35400Short Interest ↑Analyst RevisionDYNDyne Therapeutics3.1855 of 5 stars$26.05+1.2%$50.42+93.5%+106.0%$2.65BN/A-7.23100CPRXCatalyst Pharmaceuticals4.6439 of 5 stars$21.83+2.1%$31.14+42.7%+53.5%$2.60B$398.20M18.12167Short Interest ↑HCMHUTCHMED2.5385 of 5 stars$14.91-4.3%$19.00+27.4%-23.1%$2.60B$838M0.001,988AGIOAgios Pharmaceuticals4.355 of 5 stars$43.80+12.4%$56.33+28.6%+80.6%$2.50B$32.87M3.73390Analyst RevisionPTGXProtagonist Therapeutics3.653 of 5 stars$41.42+0.8%$53.78+29.8%+93.1%$2.47B$60M15.44125Positive NewsIOVAIovance Biotherapeutics4.0758 of 5 stars$7.89+0.8%$22.33+183.1%+0.4%$2.40B$1.19M-5.25500Short Interest ↑AMRXAmneal Pharmaceuticals2.193 of 5 stars$7.74-1.1%$10.00+29.2%+55.5%$2.40B$2.39B-11.517,700Positive NewsLBPHLongboard Pharmaceuticals1.2893 of 5 stars$59.98+0.0%$59.56-0.7%+1,094.8%$2.34BN/A-26.9020 Related Companies and Tools Related Companies Bausch Health Companies Competitors Arrowhead Pharmaceuticals Competitors Dyne Therapeutics Competitors Catalyst Pharmaceuticals Competitors HUTCHMED Competitors Agios Pharmaceuticals Competitors Protagonist Therapeutics Competitors Iovance Biotherapeutics Competitors Amneal Pharmaceuticals Competitors Longboard Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AUTL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
